Citric Acid

SCHEMBL30951847

COc1ccc(CNc2nc(N3CCC[C@H]3COC(=O)CCC[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-])ncc2C(=O)NCc2ncccn2)cc1Cl.O=C(O)CC(O)(CC(=O)O)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACVR1 ADORA1 ADORA2A ADORA2B ADORA3 ESR1 ESR2 FLT3 GRIN1 GRIN2A GRIN2B GRIN2C GRIN2D GRIN3A GRIN3B GSC1 HRH1 HTR7 IDH1 IDH2 IRAK1 JAK1 JAK2 JAK3 MEN1 OPRM1 P2RX3 PDE5A SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SIGMAR1 SLC6A2 SYK TACR1 TOP2A TYK2

The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

	gene	UniProt	supporting neighbours	confidence
▸	PDE5A known ✓	O76074	12/20	0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31028931	0.95	PDE5A (0.66)	PDE5A
SCHEMBL21705400	0.95	PDE5A (0.66)	PDE5A
SCHEMBL21682579	0.95	PDE5A (0.66)	PDE5A
SCHEMBL21682583	0.95	PDE5A (0.66)	PDE5A
Citric Acid SCHEMBL23924112	0.94	PDE5A (0.59)	PDE5A
Citric Acid SCHEMBL21682532	0.94	PDE5A (0.59)	PDE5A
Citric Acid SCHEMBL30052405	0.94	PDE5A (0.59)	PDE5A
Citric Acid SCHEMBL21682535	0.91	PDE5A (0.63)	PDE5A
Citric Acid SCHEMBL21682537	0.91	PDE5A (0.63)	PDE5A
Citric Acid SCHEMBL30052402	0.91	PDE5A (0.63)	PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11980618-B2	Nitric oxide releasing phosphodiesterase type 5 inhibitor	NICOX S.A. (FR)	2024-05-14	—	—	US	claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11980618-B2	Nitric oxide releasing phosphodiesterase type 5 inhibitor	PDE5A, PDE3A, PDE3B	PDE5A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.